Paul Tudor Jones Mirati Therapeutics, Inc. Transaction History

Tudor Investment Corp Et Al

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$41.99 - $62.38 $7.2 Million - $10.7 Million	171,537 New	171,537 $10.1 Million
Q4 2022 Feb 14, 2023	BUY	$41.27 - $98.62 $1.27 Million - $3.04 Million	30,799 New	30,799 $1.4 Million
Q2 2022 Aug 15, 2022	SELL	$39.16 - $88.71 $823,926 - $1.87 Million	-21,040 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$75.82 - $150.97 $1.6 Million - $3.18 Million	21,040 New	21,040 $1.73 Million
Q4 2021 Feb 14, 2022	SELL	$132.01 - $190.29 $575,563 - $829,664	-4,360 Closed	0 $0

Q3 2021 Nov 15, 2021	SELL	$132.13 - $177.45 $3.2 Million - $4.3 Million	-24,208 Reduced 84.74%	4,360 $771,000
Q2 2021 Aug 16, 2021	BUY	$144.0 - $179.73 $4.11 Million - $5.13 Million	28,568 New	28,568 $4.62 Million
Q4 2020 Feb 16, 2021	SELL	$162.05 - $240.27 $2.63 Million - $3.9 Million	-16,242 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$113.26 - $167.27 $1.52 Million - $2.24 Million	13,383 Added 468.1%	16,242 $2.7 Million
Q2 2020 Aug 14, 2020	BUY	$72.01 - $120.39 $205,876 - $344,195	2,859 New	2,859 $326,000

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.